Involvement of the peripheral cholinergic muscarinic system in the compensatory ovarian hypertrophy in the rat.
In the present experiments, unilateral ovariectomy (ULO) induced compensatory hypertrophy (COH) of the remaining rat ovary (60%-85% increase in ovarian weight, total proteins, and total RNA and DNA). An increased thymidine uptake preceded the organ enlargement. COH was inhibited by i.p.-administered muscarinic antagonist propantheline (dose-dependently) or botulinum toxin delivered locally to the ovary. The effects were reversed by bethanecol i.p. (a muscarinic agonist). In sham ULO animals, [3H]-scopolamine binding to ovarian membranes indicated the existence of muscarinic receptors (Kd 2.5 nM, Bmax 12 fmol/mg proteins, Hill 1.0). The ovarian 1,2-diacylglycerol (DAG) was 120-150 pmol/mg tissue and did not react to carbachol in vitro (50 microM). At 15 minutes after ULO, the [3H]-scopolamine binding was unchanged (Kd 2.6 nM, Bmax 12.6 fmol/mg tissue, Hill 1.0), but the ovarian DAG was increased (280-350 pmol/mg tissue) and increased further in response to carbachol (460-550 pmol/mg tissue). After ULO, ovarian DAG remained continuously responsive to carbachol. The ULO-induced DAG increase and enhanced susceptibility to carbachol were inhibited by the botulinum toxin or atropine pretreatments. Abdominal vagotomy done immediately before ULO also inhibited the ULO-induced DAG increase and DAG responsiveness to carbachol. However, when the vagotomy was performed 10 mins after ULO, the ovarian DAG remained responsive to carbachol in vitro. The data suggest that the peripheral cholinergic system, including the ovarian muscarinic receptors, stimulates COH. This is apparently associated with the ULO-induced coupling of the ovarian muscarinic receptors to phosphoinositide (PI) breakdown. Vagus plays a role in the occurrence of the changed muscarinic receptor-PI breakdown relationship in the remaining ovary.
Trkulja
Vladimir
V
Department of Pharmacology, Croatian Brain Research Institute, Zagreb University School of Medicine, Zagreb, Croatia. vladimir.trkulja@zg.htnet.hr
Crljen-Manestar
Vladiana
V
Banfic
Hrvoje
H
Lackovic
Zdravko
Z
D000818:Animals; D001665:Binding Sites; D002217:Carbachol / Q000494:pharmacology; D004075:Diglycerides / Q000378:metabolism; D005260:Female; D007839:Functional Laterality; D006984:Hypertrophy; D010052:Ovariectomy; D010053:Ovary / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D017208:Rats, Wistar; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*; D012601:Scopolamine / Q000493:pharmacokinetics; D014628:Vagotomy
D004075:Diglycerides; D011976:Receptors, Muscarinic; D002217:Carbachol; D012601:Scopolamine